Browsing Det matematisk-naturvitenskapelige fakultet by Author "Løndalen, Ayca"
Now showing items 1-4 of 4
-
Løndalen, Ayca; Blakkisrud, Johan; Rootwelt-Revheim, Mona Elisabeth; Dahle, Jostein; Kolstad, Arne; Stokke, Caroline (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)Abstract Purpose [ 177 Lu]Lu-lilotomab satetraxetan, a novel CD37 directed radioimmunotherapy (RIT), has been investigated in a first-in-human phase 1/2a study for relapsed indolent non-Hodgkin ...
-
Løndalen, Ayca; Blakkisrud, Johan; Rootwelt-Revheim, Mona-Elisabeth; Madsbu, Ulf Erik; Dahle, Jostein; Kolstad, Arne; Stokke, Caroline (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2020)Purpose 177Lu-lilotomab satetraxetan targets the CD37 antigen and has been investigated in a first-in-human phase 1/2a study for relapsed non-Hodgkin lymphoma (NHL). Tumor dosimetry and response evaluation can be ...
-
Blakkisrud, Johan; Løndalen, Ayca; Dahle, Jostein; Martinsen, Anne Catrine Trægde; Kolstad, Arne; Stokke, Caroline (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)Background The aim of this study was to investigate dosimetry data and clinical variables to predict hematological toxicity in non-Hodgkin lymphoma (NHL) patients treated with [177Lutetium]Lu-lilotomab satetraxetan. Material ...
-
Stokke, Caroline; Blakkisrud, Johan; Løndalen, Ayca; Dahle, Jostein; Martinsen, Anne Catrine Trægde; Holte, Harald; Kolstad, Arne (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)Purpose: 177Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been ...